SNE-101 / S&E bio - LARVOL DELTA

The STem Cell-derived Extracellular Vesicle Therapy In Acute Ischemic Stroke (STEVIA) (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: S&Ebio Co. Ltd. | Not yet recruiting ➔ Recruiting | Trial primary completion date: Mar 2026 ➔ Mar 2027

Enrollment open • Trial primary completion date • Cardiovascular • Ischemic stroke

Multimodal Antiatherosclerotic Effects of Clinical-Grade Mesenchymal Stem Cell-Derived Extracellular Vesicles. (PubMed, Stroke) - "By enhancing cholesterol efflux, suppressing PCSK9 and Lp(a), and reducing systemic inflammation, SNE-101 addresses critical cardiovascular risks. This provides strong mechanistic guidance for its application in ongoing clinical trials for acute ischemic stroke."

Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • Inflammation • Ischemic stroke • ABCA1 • APOE • PPARG